{"id":39768,"date":"2025-08-20T14:05:24","date_gmt":"2025-08-20T06:05:24","guid":{"rendered":"https:\/\/flcube.com\/?p=39768"},"modified":"2025-08-20T14:05:25","modified_gmt":"2025-08-20T06:05:25","slug":"xtalpi-collaborates-with-dong-a-st-on-ai-driven-drug-discovery-for-immunological-diseases","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=39768","title":{"rendered":"XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases"},"content":{"rendered":"\n

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228<\/a>) and Korea’s leading pharmaceutical company, Dong-A ST, have signed a Memorandum of Understanding (MOU) to jointly develop therapeutics for immunological and inflammatory diseases. This strategic collaboration leverages XtalPi’s cutting-edge AI-driven drug discovery platform.<\/p>\n\n\n\n

AI-Driven Drug Discovery Platform<\/strong>
XtalPi’s platform integrates artificial intelligence (AI), quantum physics, and large-scale automated robotic experiments. The two companies will co-identify targets and discover first-in-class or best-in-class drug candidates. This innovative approach combines AI’s speed and generative power with the accuracy of robotic experimentation, significantly expanding the chemical space for drug discovery.<\/p>\n\n\n\n

Dong-A ST\u2019s Strategic Expansion<\/strong>
Dong-A ST aims to strengthen its pipeline in immunology and inflammation and expand its R&D scope beyond small molecule therapeutics. The company will actively participate in the entire R&D process, leveraging its expertise in immunology, inflammation, and small molecule drug development.<\/p>\n\n\n\n

Future Collaboration and Commercial Potential<\/strong>
The partnership highlights Dong-A ST’s commitment to diversifying its R&D portfolio and exploring new commercialization opportunities. By combining XtalPi’s advanced technology with Dong-A ST’s rich experience, the collaboration is poised to drive innovation and address unmet medical needs in immunological and inflammatory diseases.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) and Korea’s leading pharmaceutical company, Dong-A…<\/p>\n","protected":false},"author":1,"featured_media":39769,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,65,4297,1112,695,70,696],"class_list":["post-39768","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-adc-xdc","tag-auto-immune","tag-dong-a-st","tag-hkg-2228","tag-quantumpharm","tag-tpd","tag-xtalpi"],"yoast_head":"\nXtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) and Korea's leading pharmaceutical company, Dong-A ST, have signed a Memorandum of Understanding (MOU) to jointly develop therapeutics for immunological and inflammatory diseases. This strategic collaboration leverages XtalPi's cutting-edge AI-driven drug discovery platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=39768\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases\" \/>\n<meta property=\"og:description\" content=\"Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) and Korea's leading pharmaceutical company, Dong-A ST, have signed a Memorandum of Understanding (MOU) to jointly develop therapeutics for immunological and inflammatory diseases. This strategic collaboration leverages XtalPi's cutting-edge AI-driven drug discovery platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=39768\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-20T06:05:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-20T06:05:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2011.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39768#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39768\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases\",\"datePublished\":\"2025-08-20T06:05:24+00:00\",\"dateModified\":\"2025-08-20T06:05:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39768\"},\"wordCount\":217,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39768#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2011.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Auto-immune\",\"Dong-A ST\",\"HKG: 2228\",\"QuantumPharm\",\"TPD\",\"Xtalpi\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39768#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39768\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=39768\",\"name\":\"XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39768#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39768#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2011.webp\",\"datePublished\":\"2025-08-20T06:05:24+00:00\",\"dateModified\":\"2025-08-20T06:05:25+00:00\",\"description\":\"Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) and Korea's leading pharmaceutical company, Dong-A ST, have signed a Memorandum of Understanding (MOU) to jointly develop therapeutics for immunological and inflammatory diseases. This strategic collaboration leverages XtalPi's cutting-edge AI-driven drug discovery platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39768#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=39768\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39768#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2011.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2011.webp\",\"width\":1080,\"height\":608,\"caption\":\"XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=39768#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases - Insight, China's Pharmaceutical Industry","description":"Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) and Korea's leading pharmaceutical company, Dong-A ST, have signed a Memorandum of Understanding (MOU) to jointly develop therapeutics for immunological and inflammatory diseases. This strategic collaboration leverages XtalPi's cutting-edge AI-driven drug discovery platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=39768","og_locale":"en_US","og_type":"article","og_title":"XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases","og_description":"Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) and Korea's leading pharmaceutical company, Dong-A ST, have signed a Memorandum of Understanding (MOU) to jointly develop therapeutics for immunological and inflammatory diseases. This strategic collaboration leverages XtalPi's cutting-edge AI-driven drug discovery platform.","og_url":"https:\/\/flcube.com\/?p=39768","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-20T06:05:24+00:00","article_modified_time":"2025-08-20T06:05:25+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2011.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=39768#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=39768"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases","datePublished":"2025-08-20T06:05:24+00:00","dateModified":"2025-08-20T06:05:25+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=39768"},"wordCount":217,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=39768#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2011.webp","keywords":["ADC \/ XDC","Auto-immune","Dong-A ST","HKG: 2228","QuantumPharm","TPD","Xtalpi"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=39768#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=39768","url":"https:\/\/flcube.com\/?p=39768","name":"XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=39768#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=39768#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2011.webp","datePublished":"2025-08-20T06:05:24+00:00","dateModified":"2025-08-20T06:05:25+00:00","description":"Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228) and Korea's leading pharmaceutical company, Dong-A ST, have signed a Memorandum of Understanding (MOU) to jointly develop therapeutics for immunological and inflammatory diseases. This strategic collaboration leverages XtalPi's cutting-edge AI-driven drug discovery platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=39768#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=39768"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=39768#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2011.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2011.webp","width":1080,"height":608,"caption":"XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=39768#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"XtalPi Collaborates with Dong-A ST on AI-Driven Drug Discovery for Immunological Diseases"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2011.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39768"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39768\/revisions"}],"predecessor-version":[{"id":39771,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/39768\/revisions\/39771"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/39769"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}